Monitor the upcoming 10-Q for the quarter ending October 31, 2026 (first period under Grassi) for any restatements, changes in accounting policies, or new material weakness disclosures. The auditor change at a small-cap biotech with known material weaknesses warrants close scrutiny of future financial filings.
Price Chart
Executive Summary
PharmaCyte Biotech dismissed its auditor, CBIZ CPAs, and engaged Grassi & Co. as its new independent registered public accounting firm, effective October 14, 2026. The change was not due to any disagreements, but the company disclosed pre-existing material weaknesses in internal control over financial reporting (insufficient segregation of CFO duties and management review controls). Auditor switches at small biotechs often raise concerns about financial reporting quality, though the lack of disagreements and the auditor's unqualified opinions on prior years' financials somewhat mitigate the risk.
Key Facts
- Auditor dismissed: CBIZ CPAs P.C., effective October 14, 2026.
- New auditor engaged: Grassi & Co., CPAs, P.C., effective same date.
- No disagreements on accounting principles or audit scope during fiscal years ended April 30, 2026 and 2025, or subsequent interim period.
- Prior auditor's reports for fiscal years ended April 30, 2026 and 2025 were unqualified — no adverse opinion or disclaimer.
- Material weaknesses in internal control over financial reporting were previously disclosed: insufficient segregation of CFO duties and insufficient management review controls.
- CBIZ CPAs agreed with the company's statements in the 8-K (per Exhibit 16.1 letter).
Financial Impact
No financial figures disclosed; the filing is a change in auditor with no restatement or financial impact stated.
Risk Factors
- Potential for undisclosed accounting issues or future restatements despite no current disagreements.
- Material weaknesses in internal controls may persist or worsen under new auditor, increasing risk of financial reporting errors.
- Small biotech with auditor switch may face increased scrutiny from regulators or lenders.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007934 |
| Document: pharmacyte_ex1601.htm | 0001683168-26-007934 |
| Document: 0001683168-26-007934-index-headers.html | 0001683168-26-007934 |
| Document: 0001683168-26-007934-index.html | 0001683168-26-007934 |
| Document: 0001683168-26-007934.txt | 0001683168-26-007934 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers